Press Releases
The latest announcements and insights from TopStocks.
September 1, 2026
AEye’s Apollo™ long-range lidar has been selected by Lunar Outpost for integration onto the Pegasus Lunar Terrain Vehicle, marking a multi-million-dollar commercial engagement and AEye’s entry into the emerging space mobility market supporting NASA’s Artemis lunar program.
August 28, 2026
Cosmos Health has retired its $8 million senior secured ATW convertible note one year ahead of maturity, eliminating further dilution from conversions while reducing operating cash requirements, simplifying its capital structure and continuing its $5 million share repurchase program.
August 18, 2026
TruGolf Holdings has agreed to acquire Polymath Research Inc., bringing the developer of the institutional-grade Polymesh Layer-1 blockchain to the Nasdaq public markets and expanding TruGolf into regulated digital-asset tokenization infrastructure.
July 30, 2026
ZenaTech says its newly acquired Velocity Geomatics business is entering a stronger Western Canadian energy market supported by higher oil prices and more than US$500 billion in expected industry investment over the next decade.
July 28, 2026
ZenaTech’s ZenaDrone has begun flight testing its low-cost Interceptor P-1 autonomous counter-UAS platform, advancing the company’s integrated defense system for intercepting hostile drones and coordinated drone swarms.
July 13, 2026
Oncolytics Biotech is preparing for an FDA Type D meeting to discuss a potential registrational pathway for pelareorep while rapidly activating clinical sites for its randomized REO 033 colorectal cancer trial.
June 22, 2026
Through its Eva Defense subsidiary, Eva Live is forming a dedicated internal cybersecurity task force to move hard and fast on acquisitions and partnerships.
June 16, 2026
Oncolytics Biotech announced that the United States Patent and Trademark Office has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep, expected to provide intellectual property protection into 2044.
June 12, 2026
Cosmos Health reported that its C-Scrub and C-Sept antiseptic brands have generated over $1.5 million in combined annualized sales across the UK and Greece, with plans to expand across the EU targeting $7.4 million in annual revenue and $5.3 million in gross profit within three years.
June 11, 2026
Cosmos Health announced that it has been granted an additional 180-day period, through December 7, 2026, to regain compliance with the Nasdaq minimum bid price requirement.
June 05, 2026
Cosmos Health announced the U.S. launch of Oliv18, expanding its 18 Series nutraceutical platform into cardiovascular and antioxidant categories with a USDA and EU organic certified, 100% solvent-free, whole olive polyphenol formulation from the Moroccan Saharan desert.
June 04, 2026
Cosmos Health announced that 96 Sky Premium Life products are now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand’s international distribution footprint and consumer accessibility across Europe.
June 04, 2026
Cosmos Health identified approximately $20 million in non-core assets available for monetization, including real estate, digital assets, marketable securities, and other liquid assets, with potential proceeds to fund acquisitions, reduce debt, and unlock shareholder value.
June 02, 2026
Greenland Mines appointed WSP Denmark to continue environmental baseline work at the Sarfartoq rare earth project in southwest Greenland, advancing second-year environmental studies ahead of a future Environmental Impact Assessment.
June 02, 2026
Cosmos Health provided a balance sheet update highlighting European Investment Bank financing discussions for up to €25 million, the expiration of Series B Warrants with no dilution, strengthening equity, real estate asset value, and reaffirmed long-term growth guidance.
June 01, 2026
Cosmos Health announced the planned launch of a veterinary formulation of C-Scrub Wash 4%, marking the company’s first entry into the animal health market following successful European veterinary disinfectant standards testing.
April 30, 2026
Cadrenal Therapeutics announced it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance on key elements of a pivotal Phase 3 trial for CAD-1005 in heparin-induced thrombocytopenia.
April 16, 2026
Company expands into new boat sales with Sportsman and Phenom brands, leveraging a unique storage ecosystem to drive recurring revenue and long-term customer retention
April 09, 2026
Company introduces a scalable five-tier broker model designed to accelerate global expansion, increase transaction activity, and empower brokers to build high-income businesses
April 06, 2026
New locations in Rhode Island and New Jersey enhance regional market density, increase transaction flow, and support continued broker hiring
April 02, 2026
Off The Hook Yachts announced a definitive agreement to acquire Bellhart Marine Group and its affiliated entities, expanding its in-house marine service, refit, and reconditioning capabilities across a three-location platform in the Carolinas.
April 01, 2026
Off The Hook YS Inc. announced a corporate update highlighting its operational momentum in the first quarter of 2026 following a record 2025, citing expanded inventory financing capacity, a larger broker network, infrastructure growth, and continued investment in its AI-powered marine marketplace platform.
March 30, 2026
Off The Hook Yachts reported record 2025 revenue of $119.9 million, sold a record 426 boats, raised 2026 revenue guidance to $150 million-$155 million, and highlighted stronger liquidity following its November 2025 IPO.
March 16, 2026
Auddia highlighted the strategic relevance of its LT350 distributed AI infrastructure platform following new institutional research indicating that hyperscale AI datacenters have become military targets in the Iran war and are now considered exposed infrastructure during geopolitical conflicts.
March 12, 2026
Cadrenal Therapeutics highlighted recent scientific findings showing the potential of its first-in-class 12-LOX inhibitor, CAD-1005, to target inflammatory consequences of obesity and Type 2 diabetes.
March 11, 2026
Auddia announced that LT350 signed a non-binding LOI with a NYSE listed medical REIT to host LT350’s first pilot solar-integrated AI micro-datacenter canopy, expected to be at a hospital property in the Dallas Fort Worth MSA.
March 09, 2026
AI-first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced its official brand activation for Discovr Radio at the 2026 South by Southwest® (SXSW®) Conference and Festivals.